I’m excited to share our latest free feature: The Psychedelic News Feed. This webpage aims to serve as a one-stop destination for the latest media
NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of
WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions
This preliminary data provides an early look at how deuterated psychedelics perform in the clinic compared to their non-deuterated counterparts. Besides offering a potentially clearer
On Saturday October 7th California’s Governor, Gavin Newsom, returned Senate Bill 58 to the Senate without his signature, effectively vetoing it. As a reminder, SB
*** Listening Session #5 – Cultivation and Manufacturing Practices Part 1 Following formalities, Dominique Mendiola gave an overview of DOR’s statutory requirements under Title 44
I’m excited to share our latest free feature: The Psychedelic News Feed. This webpage aims to serve as a one-stop destination for the latest media
WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions
NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of
I’m excited to share our latest free feature: The Psychedelic News Feed. This webpage aims to serve as a one-stop destination for the latest media